Good EULAR Response in Patients With Early Rheumatoid Artrhitis (EARLY RA)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2015 by Pfizer
Information provided by (Responsible Party):
Pfizer Identifier:
First received: February 15, 2012
Last updated: March 12, 2015
Last verified: March 2015

This open-label, prospective, observational study will evaluate the clinical response to etanercept + methotrexate therapy in patients with moderate to severe rheumatoid arthritis, as prescribed by the rheumatologist in a normal clinical setting in Greece

Condition Intervention Phase
Rheumatoid Arthritis
Drug: etanercept
Drug: methotrexate
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Ability To Achieve A Good Eular Response In Patients With Moderate-to-severe Active Early Rheumatoid Arthritis Who Satisfy The New Acr/Eular Classification Criteria Receiving Etanercept + Mtx In Real World Clinical Practice In Greece

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Percentage of patients that achieved Good EULAR response based on DAS28 EULAR response criteria [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change from baseline in each component of DAS28 [ Time Frame: baseline, 6 months ] [ Designated as safety issue: No ]
  • Change from baseline in HAQ-DI [ Time Frame: baseline, 6 months ] [ Designated as safety issue: No ]
  • Change from baseline in EQ-5D [ Time Frame: baseline, 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 150
Study Start Date: March 2013
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
etanercept + methotrexate Drug: etanercept
according to SmPC and clinical practice
Drug: methotrexate
according to SmPC and clinical practice

Detailed Description:

All subjects enrolled should meet the usual prescribing criteria for Etanercept as per the local product information and should be entered into the study at the investigator's discretion


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients with rheumatoid arthritis who fulfill the inclusion/exclusion criteria


Inclusion Criteria:

  1. signed and dated informed consent document
  2. 18 years of age and older at the time of consent
  3. Patients with moderate-to-severe active rheumatoid arthritis, who satisfy the 2010 Rheumatoid Arthritis Classification Criteria
  4. Patients who have been prescribed for first time to receive treatment with MTX + Etanercept prior to enrollment to this study, following routine clinical practice and according to the approved SmPC,
  5. Patients with DAS28 ≥ 3.2
  6. Duration of disease symptoms ≥ 6 weeks and ≤2 years
  7. Failure to respond to prior DMARDs including MTX monotherapy according to routine clinical practice.

Exclusion Criteria:

  1. Contraindications according to the SmPC
  2. History of or present anti-TNFa or other biologic therapy for the treatment of RA
  3. Known significant concurrent medical disease according to investigator's opinion and the current SmPC
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01558089

Contact: Pfizer Call Center 1-800-718-1021

G. Gennimatas General Hospital /Rheumatology Clinic Recruiting
Athens, Attica, Greece, 11527
Ippokrateio General Hospital of Athens / 2nd internal Medicine Clinic of the University of Athens Recruiting
Athens, Attica, Greece, 11527
University General Hospital of Heraklion Recruiting
Heraklion, Creete, Greece, 71110
G. Papanikolaoy Recruiting
Thessaloniki, Exochi, Greece, 570 10
424 Military Hospital Recruiting
Thessaloniki, Thessalonikis, Greece
Laiko General Peripheral Hospital Recruiting
Athens, Greece, 115 27
G. Chatzikosta General Hospital of Ioannina / Internal Medicine section, Rheumatology Unit Not yet recruiting
Ioannina, Greece, 450 01
Peripheral University General Hospital of Larissa Recruiting
Larissa, Greece, 41 222
"Agios Andreas" General Hospital of Patras Not yet recruiting
Patras, Greece, 26335
"Olympion therapeutic center" General Clinic of Patras Recruiting
Patras, Greece, 26443
Ippokratio Not yet recruiting
Thessaloniki, Greece, 546 42
Papageorgiou General Hospital of Thessaloniki / Rheumatology department Not yet recruiting
Thessaloniki, Greece, 56429
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer Identifier: NCT01558089     History of Changes
Other Study ID Numbers: B1801138
Study First Received: February 15, 2012
Last Updated: March 12, 2015
Health Authority: Greece: Ethics Committee

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases processed this record on March 26, 2015